Expression Of Serum TPS,VEGF In Breast Cancer And Their Relationships With Clinical And Pathological Characteristics

BACKGROUND: Breast cancer is one of the most common malignant tumors of women. It is of great value to find an ideal tumor marker for early diagnosis of breast cancer, appreciation of the therapeutic effect and monitoring the prognosis. TPS (Tissue polypeptide specific antigen) is a kind of soluble fragment of 18C termini of cytokeratin and a molecular marker of epidermic tumor. Vascular endothelial growth factor (VEGF), is also called vascular permeability factor, special acting on vascular endothelial cell. It is a most functional and typical angiogenesis-promoting factor. ELISA was applied in this research to investigate the serum expression of TPS,VEGF in patients with breast cancer and investigate their relationships with clinical and pathological characteristics.OBJECTIVE: To investigate the serum expression of TPS,VEGF in patients with breast cancer and investigate their relationships with clinical and pathological characteristics.METHODS: 50 patients with breast cancer, 15 with breast fibroadenoma and 10 healthy controls were selected. Enzyme Linked Immunosorbent Assay (ELISA) was applied to test TPS,VEGF concentration. T-test,X~2 test and Pearson,Spearman correlation were applied to determine if there are relationships between the expression of TPS,VEGF and clinical and pathological characteristics.RESULT: 1.Serum TPS /VEGF concentration is higher in malignant group than in benign and control group, the difference is of statistical significance (P<0.01) . But there is no statistical significance between the results of benign and normal control; 2. mutual comparisons made between 0,I, II and III stages respectively showed that there was no statistical significance between 0 and I stage (P>0.05) ,but the results of other mutual comparison are significantly different (P<0..01); 3.In 50 primarily breast cancer patients who have received modified radical mastectomy, Serum TPS/VEGF concentration declines, the decline was statistical difference (P<0..01) 4. In 50 primarily breast cancer patients, the concentration of TPS was not statistically different regarding the diameter of the mass (2cm). But the serum concentration of VEGF was statistically different regarding the diameter of the mass (2cm) and there is statistical significance (P<0.01) ; the concentration of TPS is statistically significantly different between the positive and negative of ER/PR patients, as well as CerBb-2. serum concentration of TPS significantly correlates with ER, PR and CerBb-2. For TPS and VEGF ,in regarding of the axillary lymph nodes metastasis, there are also significantly differences whether the number of metastatic lymph nodes. 5. In general, the sensitivity was 70%, specificity was 92% for TPS, the sensitivity was 56%, specificity was 84% for VEGF. Serum concentration of TPS significantly correlates with Serum concentration of VEGF.CONCLUSION: 1. The high serum expression of TPS,VEGF in breast cancer clue to the both can be used as tumor marker for diagnosis of breast cancer. 2. serum concentration of TPS significantly correlates with axillary metastasis, ER, PR, and CerBb-2, indicating that TPS is probably useful in evaluation and prognosis prediction of breast cancer.3.serum concentration of VEGF significantly correlates with axillary metastasis, indicating that VEGF is probably useful in prognosis prediction of breast cancer.